[04-January-2024]

[2024年1月4日]

Health Canada's approval of ABRYSVO helps to address the urgent need to minimize the spread of RSV infections – a disease with flu-like symptoms that can result in respiratory distress,1,2,3 and lead to serious infection such as bronchitis or pneumonia, requiring hospital treatment4

加拿大卫生部批准ABRYSVO有助于解决减少RSV感染传播的迫切需要，RSV感染是一种具有流感样症状的疾病，可导致呼吸窘迫1、2、3，并导致支气管炎或肺炎等严重感染，需要住院治疗4

ABRYSVO is the only RSV vaccine authorized in Canada for maternal immunization

ABRYSVO是加拿大唯一授权用于产妇免疫的RSV疫苗

KIRKLAND, QC, Jan. 4, 2024 /CNW/ - Pfizer Canada ULC announces today the Health Canada approval of ABRYSVOTM, its bivalent Respiratory Syncytial Virus (RSV) vaccine. The vaccine is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older by active immunization, and the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals..

柯克兰，QC，2024年1月4日/CNW/-辉瑞加拿大ULC今天宣布加拿大卫生部批准其二价呼吸道合胞病毒（RSV）疫苗ABRYSVOTM。该疫苗适用于通过主动免疫预防60岁及以上人群中由RSV引起的下呼吸道疾病，以及通过孕妇的主动免疫预防从出生到6个月大的婴儿中由RSV引起的下呼吸道疾病和严重下呼吸道疾病。。

RSV is a common respiratory virus that causes mild disease with cold-like symptoms. In more vulnerable populations, like adults 60 and over, an RSV infection can be severe, especially among those with underlying respiratory or cardiac conditions.5 For infants, RSV infection can result in respiratory distress, especially in those less than six months of age, and those with higher risk factors such as congenital heart or lung disease, or prematurity.6,7,8.

RSV是一种常见的呼吸道病毒，可引起轻度疾病，并伴有类似感冒的症状。在更脆弱的人群中，如60岁及以上的成年人，RSV感染可能很严重，尤其是那些有潜在呼吸或心脏疾病的人群。对于婴儿，RSV感染可导致呼吸窘迫，特别是在6个月以下的人群中，以及先天性心脏病或肺病或早产等高危因素的人群[6,7,8]。

'RSV is a virus that we need to put a spotlight on. It spreads easily and it's not something you can completely avoid,' said Laura Tamblyn Watts,  founder and CEO of CanAge. 'Older adults living in congregate settings or long-term care, which is over 500,000 Canadians,9 have a higher risk of becoming infected with RSV.10 It's important for all of us to be mindful of RSV prevention to help protect our loved ones and more vulnerable populations.'.

CanAge创始人兼首席执行官劳拉·塔布林·瓦茨（LauraTamblynWatts）说，RSV是一种我们需要关注的病毒。它很容易传播，并且不是你可以完全避免的居住在聚集场所或长期护理的老年人（超过50万加拿大人）9感染RSV的风险更高。我们所有人都必须注意RSV的预防，以帮助保护我们的亲人和更脆弱的人群。”。

'Today's announcement means Canada has a new option to help protect those most at risk from the severity of RSV infections,' said Andréa Mueller, Primary Care Portfolio Lead at Pfizer Canada. 'For those eligible to receive the vaccine, getting vaccinated means helping to ensure babies are protected from their first breath, and helping older adults continue doing what they love with minimized risk of becoming infected.

辉瑞（Pfizer Canada）初级保健投资组合负责人安德烈·穆勒（AndréaMueller）说，今天的宣布意味着加拿大有了一个新的选择，可以帮助保护那些面临RSV感染严重风险的人对于那些有资格接种疫苗的人来说，接种疫苗意味着帮助确保婴儿免受第一次呼吸的影响，并帮助老年人继续做他们喜欢做的事情，将感染风险降至最低。

At Pfizer, we take pride in our decades of experience in vaccines, helping to make a positive contribution to public health and the broader community.'  .

在辉瑞，我们为自己数十年的疫苗经验感到骄傲，这有助于为公共卫生和更广泛的社区做出积极贡献。”。

Respiratory viruses, including RSV, increase in the fall and winter months, and the impact of RSV on healthcare resources is significant. RSV infection can result in hospitalization, particularly for infants one year or younger, for whom there is an increased risk.11 Older adults also have some of the highest costs associated with the disease.12 The approval of Pfizer's vaccine will help to protect those at both early and later stages in life and will reduce the overall health and economic impact of RSV infection.12.

呼吸道病毒（包括RSV）在秋季和冬季增加，RSV对医疗资源的影响很大。RSV感染可导致住院治疗，特别是对于一岁或更小的婴儿，其风险增加[11]。老年人也有一些与疾病相关的最高成本[12]。辉瑞公司疫苗的批准将有助于保护那些在生命的早期和晚期，并将减少RSV感染对整体健康和经济的影响。

'Vaccines are considered to be the most effective tool in public health for preventing illness and can help reduce the stress on our healthcare system and professionals including nurses, doctors, and others on the frontline,' said Dr. Darine El-Chaâr, Maternal Fetal Medicine physician at The Ottawa Hospital.

渥太华医院的母胎医学医生达林·埃尔·查尔博士说：“疫苗被认为是公共卫生中预防疾病最有效的工具，可以帮助减轻我们医疗保健系统和专业人员（包括护士、医生和其他一线人员）的压力。”。

'Vaccines administered through maternal immunization can also help play a critical role in decreasing the gap of vulnerability in the first few months of an infant's life, as well as helping to protect their mothers, who may be at increased risk of severe disease compared with non-pregnant women.'13 .

“通过母亲免疫接种接种的疫苗也可以在减少婴儿生命最初几个月的脆弱性差距方面发挥关键作用，并有助于保护母亲，与非孕妇相比，母亲患严重疾病的风险可能会增加。”十三。

Pfizer Canada is currently assessing the timeline of availability for ABRYSVO and is committed to bringing supply of this vaccine to Canadians as quickly as possible.

辉瑞加拿大公司目前正在评估ABRYSVO的上市时间表，并致力于尽快向加拿大人提供这种疫苗。

About Pfizer Canada

关于辉瑞加拿大

Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world's best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life.

辉瑞加拿大ULC是辉瑞公司（Pfizer Inc.）的加拿大运营商，辉瑞公司是世界领先的生物制药公司之一。我们多元化的医疗保健组合包括一些世界上最知名和处方最多的药物和疫苗。我们运用科学和全球资源，在生活的每个阶段改善加拿大人的健康和福祉。

Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn, Facebook, Twitter or YouTube..

我们的承诺反映在我们所做的一切中，从我们的疾病意识倡议到我们的社区伙伴关系。要了解更多关于辉瑞加拿大的信息，请访问Pfizer.ca，或者在LinkedIn、Facebook、Twitter或YouTube上关注我们。。

______________________________________

______________________________________

1 Centers for Disease Control & Prevention. Respiratory Syncytial Virus Infection (RSV). https://www.cdc.gov/rsv/index.html

1疾病控制与预防中心。呼吸道合胞病毒感染（RSV）。https://www.cdc.gov/rsv/index.html

2 Vaccine. 2020 Mar 4; 38(11): 2435–2448. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049900/

2 Vaccine.2020 Mar 4;38(11): 2435–2448.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049900/

3 Government of Canada. Respiratory syncytial virus (RSV): For health professionals. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html

3加拿大政府。呼吸道合胞病毒（RSV）：适用于卫生专业人员。https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html

4 The Lung Association. Respiratory Syncytial Virus (RSV). https://www.lung.ca/lung-health/lung-disease/respiratory-syncytial-virus-rsv

4肺协会。呼吸道合胞病毒（RSV）。https://www.lung.ca/lung-health/lung-disease/respiratory-syncytial-virus-rsv

5 Government of Canada. Respiratory syncytial virus: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html

5加拿大政府。呼吸道合胞病毒：加拿大免疫指南。https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html

6 Centers for Disease Control & Prevention. Respiratory Syncytial Virus Infection (RSV). https://www.cdc.gov/rsv/index.html

6个疾病控制和预防中心。呼吸道合胞病毒感染（RSV）。https://www.cdc.gov/rsv/index.html

7 Vaccine. 2020 Mar 4; 38(11): 2435–2448. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049900/

7 Vaccine.2020 Mar 4;38(11): 2435–2448.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049900/

8 Government of Canada. Respiratory syncytial virus (RSV): For health professionals. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html

8加拿大政府。呼吸道合胞病毒（RSV）：适用于卫生专业人员。https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html

9 Statistics Canada. Impacts of the COVID-19 pandemic in nursing and residential care facilities in Canada. https://www150.statcan.gc.ca/n1/pub/45-28-0001/2021001/article/00025-eng.htm

9加拿大统计局。新型冠状病毒肺炎大流行对加拿大护理和住院护理机构的影响。https://www150.statcan.gc.ca/n1/pub/45-28-0001/2021001/article/00025-eng.htm

10 Health Link BC. Respiratory Syncytial Virus (RSV) Infection. https://www.healthlinkbc.ca/illnesses-conditions/infectious-diseases/respiratory-syncytial-virus-rsv-infection

10健康链接BC。呼吸道合胞病毒（RSV）感染。https://www.healthlinkbc.ca/illnesses-conditions/infectious-diseases/respiratory-syncytial-virus-rsv-infection

11 Wingert A, Pillay J, Moore DL, Guitard S, Vandermeer B, Dyson MP, Sinilaité A, Tunis M, Hartling L. Burden of illness in infants and young children hospitalized for respiratory syncytial virus: A rapid review. Can Commun Dis Rep 2021;47(9):381–96. https://doi.org/10.14745/ccdr.v47i09a05

11 Wingert A，Pillay J，Moore DL，Guitard S，Vandermeer B，Dyson MP，SinilaitéA，Tunis M，Hartling L.因呼吸道合胞病毒住院的婴幼儿疾病负担：快速回顾。Can Commun Dis Rep 2021；47（9）：381-96。https://doi.org/10.14745/ccdr.v47i09a05

12 Rafferty, E., Paulden, M., Buchan, S.A. et al. Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups. PharmacoEconomics. https://link.springer.com/article/10.1007/s40273-022-01142-w#citeas

12 Rafferty，E.，Paulden，M.，Buchan，S.A.等人评估了各个年龄段与RSV相关的个人医疗保健成本和疾病负担。药物经济学。https://link.springer.com/article/10.1007/s40273-022-01142-w#citeas

13 Esposito et al. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Front. Immunol. https://www.frontiersin.org/articles/10.3389/fimmu.2022.880368/full

13 Esposito等人。所有婴儿的RSV预防：哪种策略最可取？正面。免疫。https://www.frontiersin.org/articles/10.3389/fimmu.2022.880368/full

For further information:

更多信息：

Corporate Affairs Canada

加拿大公司事务部

1-866-9PFIZER (1-866-973-4937)

1-866-9辉瑞（1-866-973-4937）

corporate.affairs.canada@pfizer.com

corporate.affairs.canada@pfizer.com

SOURCE Pfizer Canada

来源：加拿大辉瑞公司